critical care ill
Conditions
Interventions
DDAVP group:desmopressin 0.3 ug/kg,30 min, once a day after the surgery.
NS group:intravenously administered with 50 ml saline for 30 min once a day.
Sponsors
he Sixth Affiliated Hospital of Sun Yat-Sen University
Eligibility
Sex/Gender
All
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: 1. patients who agreed to participate in the study and signed the informed consent form; 2. aged 18-75 years; 3. patients with 400 -1000 ml of during operative blood loss who underwent gastrointestinal surgery.
Exclusion criteria
Exclusion criteria: 1) patients with secondary surgery; 2) pregnant and lactating patients; 3) patients with blood system diseases; 4) platelets = 5×10^9/L; 5) patients who used drugs that affected coagulation system, platelet, and antipyretic analgesics; 6) patients with abnormal blood coagulation, INR > 2.0; 7) patients with habitual and psychiatric polydipsia; 8) patients with heart disease, unstable angina, pectoris and myocardial infarction within 6 months, congenital heart disease, pulmonary heart disease, and cardiac insufficiency; 9) patients with uncontrollable hypertension (blood pressure ? 180/110 mmHg); 10) patients with hemorrhagic stroke; 11) patients with type 2B von Willebrand disease; 12) patients with serum bilirubin, alanine aminotransferase, aspartate aminotransferase, urea nitrogen, and serum creatinine that were 1.5 times higher than normal; 13) fasting blood glucose ? 15 mmol/L; 14) serum sodium ? 120 g/L; 15) serum albumin ? 25 g/L; 16) patients with syndrome of inappropriate secretion of antidiuretic hormone, hyperadrenocorticism, hyperthyroidism, and hypothyroidism; 17) patients with idiopathic edema; 18) patients with bladder outlet obstruction, or urine flow ? 5 ml/s; 19) patients with central or renal diabetes insipidus; 20) patients with a history of blood transfusion within a month; 21) patients with bladder cancer or prostate cancer; 22) patients allergic to DDAVP; 23) patients treated with DDAVP within 3 months; 24) patients with a history of drug and alcohol dependence or abuse; 25) patients who participated in other clinical trials within 3 months; 26) patients who refused to participate or did not sign the informed consent form.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| changes of hemoglobin at 24 hr. after operation.;changes of hemoglobin at 0hr. after operation.; | — |
Secondary
| Measure | Time frame |
|---|---|
| volume of abdominal drainage at 8h;volume of abdominal drainage at 24h;coagulation and hemostasis function,;renal function;postoperative blood transfusion events;urine volume; | — |
Countries
China
Contacts
Public ContactKou Qiuye
the Sixth Affiliated Hospital of Sun Yat-Sen University,
Outcome results
None listed